transplant and with CKD was addressed in this guideline. When eGFR <35 mL/min, the risk of renal osteodystrophy is significantly increased, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica, and mixed uremic osteodystrophy. As such, MBD expert evaluation for CKD-MBD is conditionally recommended to exclude these conditions. Once excluded, no dose adjustment is needed when prescribing DEN, PTH/PTHrP, or ROM, but BP should be avoided. Use of DEN in this group may lead to